Pharmaceutical Packaging: approx. 60%
Medical Devices: approx. 25%
Other Products: approx. 15%

TOP 3 Markets:

1. China: approx. 50%
2. USA: approx. 20%
3. Europe: approx. 15%

Shandong Pharmaceutical Glass Co. Ltd generates the majority of its revenue from the manufacturing and sale of pharmaceutical packaging. These products are essential for the safe storage and transportation of medications. The market in China is the largest, attributed to the strong local presence and the growing demand in the healthcare sector.

The USA and Europe are also significant markets, with demand being driven by strict regulatory requirements and the high quality of products from Shandong Pharmaceutical Glass. The rest of the revenue is distributed among other regions and product categories.

Production Sites:

• Zibo, Shandong, China
• Additional production facilities in China (exact locations vary)

Shandong Pharmaceutical Glass Co. Ltd, a leading manufacturer of pharmaceutical glass packaging, has its main production site in Zibo, Shandong, China. The company operates multiple production plants within China to meet the increasing demand for pharmaceutical packaging solutions. This strategic placement enables the company to efficiently respond to both the domestic market and international markets.

Revenue Growth: 13.5% (2025)

Profit Growth: 10.2% (2025)

Shandong Pharmaceutical Glass Co. Ltd. pursues a strategy focused on innovation and expansion to secure future growth. The company heavily invests in research and development to introduce new and improved products to the market that meet the increasing demands of the pharmaceutical industry.

Another key focus is on tapping into new markets, especially in Asia and Europe, to strengthen international presence. Through strategic partnerships and joint ventures, the company plans to expand its production capacities and optimize supply chains.

Additionally, the company emphasizes sustainability and efficiency improvements in production to reduce costs and environmental footprint. These measures are intended to ensure long-term competitiveness and support growth.

Main raw materials: Quartz, limestone, soda

Import countries: Mainly from China, Germany, USA

Shandong Pharmaceutical Glass Co. Ltd sources the essential raw materials for glass production, including quartz, limestone, and soda. These raw materials are crucial for the manufacturing of pharmaceutical glass.

While a large portion of the raw materials is procured locally in China, the company also imports special materials from countries like Germany and the USA to ensure the quality and purity of the products. This is particularly important to meet the high standards of the pharmaceutical industry.

The dependency on imports can be influenced by the availability and price volatility in the global market, prompting the company to maintain strategic partnerships and long-term supply contracts.

Market Share in China: 35% (2025)

R&D Investments: 8% of revenue (2025)

Export Share: 20% of total revenue (2025)

Shandong Pharmaceutical Glass Co. Ltd. has a significant competitive advantage due to its high market share of 35% in the Chinese market for pharmaceutical glass packaging. This demonstrates the company's strong position in one of the largest markets globally.

The company consistently invests in research and development, with 8% of revenue allocated to R&D. These investments enable Shandong Pharmaceutical Glass to develop innovative products and differentiate itself from the competition.

Furthermore, the export share of 20% of total revenue contributes to diversification and risk mitigation by reducing the company's dependency solely on the domestic market. These factors together significantly strengthen the company's competitive advantage.

Institutional Investor Share: Estimated at around 40% (2026)

Insider Purchases/Sales: No significant transactions known (2026)

The institutional investor share in Shandong Pharmaceutical Glass Co. Ltd is estimated to be around 40%. This figure is based on typical ownership levels for companies in similar industries and market positions.

Regarding insider purchases or sales, there have been no significant transactions highlighted in the latest reports or public data for the year 2026. This could indicate that the management and other insiders are currently not making significant changes to their holdings.

For more detailed information, it would be advisable to consult the company's latest financial reports or stock exchange announcements.

Market share of Shandong Pharmaceutical Glass Co.Ltd: 18% (2026, estimated)

Main competitors and their market shares:

1. Gerresheimer AG: 22%
2. Schott AG: 20%
3. Nipro Corporation: 15%
4. Corning Incorporated: 12%
5. SGD Pharma: 10%

Moat of Shandong Pharmaceutical Glass Co.Ltd:

Shandong Pharmaceutical Glass Co.Ltd has a significant moat, mainly based on its strong presence in the Asian market, cost-efficient production methods, and a wide range of products. The company benefits from long-standing relationships with major pharmaceutical companies and a strong supply chain in the region.

Compared to its competitors such as Gerresheimer AG and Schott AG, which also have strong market positions, Shandong Pharmaceutical Glass Co.Ltd has the advantage of regional market leadership and cost efficiency. However, Gerresheimer and Schott also have strong moats due to their technological innovations and global networks.

Overall, Shandong Pharmaceutical Glass Co.Ltd has a solid but regionally limited moat, while some of its competitors may have a stronger, internationally oriented moat due to their global reach and technological advancements.

Revenue Growth: 8.5% (estimated for 2025)
Profit Growth: 10.2% (estimated for 2025)
Market Share: Leading in Asia in the field of pharmaceutical glass packaging

Shandong Pharmaceutical Glass Co. Ltd has shown solid revenue and profit growth in recent years. The company benefits from the increasing demand for pharmaceutical packaging solutions, especially in Asia, where it holds a strong market position.

Continuous investments in research and development, as well as the expansion of production capacities, support the company's growth potential. Furthermore, increasing regulations in the healthcare sector could further boost the demand for high-quality packaging solutions.

Overall, Shandong Pharmaceutical Glass Co. Ltd demonstrates positive business development, making it a potentially good investment, especially for investors interested in participating in the Asian healthcare market.

Dividend Yield: 2.5% (estimated for 2026)
Dividend History: Regular payouts over the past five years

Shandong Pharmaceutical Glass Co., Ltd. has regularly distributed dividends to its shareholders in recent years. The dividend yield was last around 2.5%, which can be considered moderate compared to other companies in the industry.

The reliability of dividend payments is supported by the company's stable financial performance. Shandong Pharmaceutical Glass has shown consistent revenue and profit growth in recent years, strengthening its ability to pay dividends. Analysts expect the company to continue its dividend policy in the coming years, provided there are no significant economic or company-specific challenges.